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ABSTRACT Atomic force microscopy has been employed to investigate the structural organization of amyloid fibrils
produced in vitro from three very different polypeptide sequences. The systems investigated are a 10-residue peptide derived
from the sequence of transthyretin, the 90-residue SH3 domain of bovine phosphatidylinositol-3-kinase, and human
wild-type lysozyme, a 130-residue protein containing four disulfide bridges. The results demonstrate distinct similarities
between the structures formed by the different classes of fibrils despite the contrasting nature of the polypeptide species
involved. SH3 and lysozyme fibrils consist typically of four protofilaments, exhibiting a left-handed twist along the fibril axis.
The substructure of TTR10–19 fibrils is not resolved by atomic force microscopy and their uniform appearance is suggestive
of a regular self-association of very thin filaments. We propose that the exact number and orientation of protofilaments within
amyloid fibrils is dictated by packing of the regions of the polypeptide chains that are not directly involved in formation of the
cross- core of the fibrils. The results obtained for these proteins, none of which is directly associated with any human
disease, are closely similar to those of disease-related amyloid fibrils, supporting the concept that amyloid is a generic
structure of polypeptide chains. The detailed architecture of an individual fibril, however, depends on the manner in which the
protofilaments assemble into the fibrillar structure, which in turn is dependent on the sequence of the polypeptide and the
conditions under which the fibril is formed.
INTRODUCTION
A range of debilitating human diseases is associated with
the conversion of proteins, or fragments of proteins, from
their normally soluble forms into insoluble fibrils or
plaques, which accumulate in a variety of organs (Kelly,
1998; Lansbury, 1999; Perutz, 1999). The insoluble mate-
rial, known as amyloid, has a well-defined fibrillar struc-
ture. The diseases associated with amyloid can be sporadic,
inherited, or even infectious, and the protein aggregates are
thought to be the direct or indirect origin of the disease in
question. These include Alzheimer’s and Parkinson’s dis-
eases, the spongiform encephalopathies such as Creutzfeldt-
Jakob disease, and adult-onset (type II) diabetes (Serpell et
al., 1997; Koo et al., 1999). Remarkably, despite the range
of proteins involved in these diseases, all of which have
unique and characteristic native folds, the fibrils in which
they are found in the disease states have structurally similar
characteristics (Sunde et al., 1997). Striking evidence has
recently accumulated suggesting that the ability to form
amyloid is not a peculiarity of this small group of disease-
related proteins (Guijarro et al., 1998b; Chiti et al., 1999)
but, rather, that the ability to form amyloid is a generic
property of the polypeptide chain. The phenomenon can be
explained by the fact that the intermolecular bonds that
stabilize this material involve the peptide backbone, which
is common to all proteins (Dobson, 1999).
Three-dimensional models have been generated to de-
scribe the assembly of fibrils by a number of proteins,
including the disease-related protein human plasma protein
transthyretin (Serpell et al., 1995; Blake et al., 1996; Blake
and Serpell, 1996), the A peptide implicated in Alzhei-
mer’s disease (Fraser et al., 1991; Chaney et al., 1998;
Malinchik et al., 1998; Li et al., 1999; Tjernberg et al.,
1999), and a src homology (SH3) domain that has no known
role in any disease (Jime´nez et al., 1999). The model of the
transthyretin filament consists of four protofilaments that
are associated to form a twisted fibril. Each protofilament
consists of four -sheets packed together with a separation
of1 nm, which twists along its long axis every 11.5 nm or
approximately every 24 -strands, resulting in a protofila-
ment diameter of 5–6 nm (Blake and Serpell, 1996). The
models suggested to explain the structure of A peptide
fibrils implicate pairs of -sheets assembling to form a
protofilament 2 nm in diameter, three to five of which
associate in the formation of the fibril. Solid-state nuclear
magnetic resonance (NMR) has been employed to probe the
orientation of the strands in the -sheet core of fibrils
formed by fragments of the A peptide. Whereas A34–42
adopts an anti-parallel orientation in the assembled fibrils
(Lansbury et al., 1995), the peptide A10–35 is found in a
parallel alignment of -sheets (Benzinger et al., 1998) im-
plying that the details of the protofilament structure may be
critically dependent on the exact peptide sequence and the
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conditions under which the fibril forms. Only by examining
the structures of a range of different amyloid fibrils will we
obtain a full understanding of the relationship between their
structure and formation. In the work described in this paper,
we have employed atomic force microscopy (AFM) to study
the ultrastructure of amyloid fibrils assembled from three
very different protein precursors.
AFM is now a significant contributor to the field of
structural biology (Shao and Yang, 1995; Shao et al., 1995;
Shao and Zhang, 1996) and several reviews have accord-
ingly been published recently (Shao et al., 1995; Engel et
al., 1999; Heinz and Hoh, 1999). The power of this method
lies in the high-resolution three-dimensional structural de-
tail attainable without the need to average over a number of
objects, combined with the ability to image samples under
controlled fluid conditions. Delicate biological specimens
can thus be spared the harsh treatments often employed in
electron microscopy (e.g., fixation or staining) or x-ray fiber
diffraction. The imaging of protein-based samples is not,
however, straightforward. The mechanical instability asso-
ciated with AFM operation in the contact mode sets a lower
limit for the imaging force that can be used, and the high
lateral loading force imparted by the scanning AFM tip
commonly leads to sample distortion, sweeping, and/or
gross image distortion. By using a tapping mode, in which
the scanning probe is oscillated sinusoidally and gently taps
the sample of interest, reproducible images of high quality
can be obtained. In this mode of operation, individual bi-
omolecules can be investigated in air or in solution (Hansma
and Hoh, 1994).
The three types of fibrils chosen for investigation repre-
sent extremes of precursor proteins that self-assemble into
amyloid. The first is composed of the 10-residue peptide
TTR10–19, derived from the sequence of the human plasma
protein transthyretin. This peptide, corresponding to an iso-
lated -strand in the native structure of TTR, has previously
been shown to assemble readily into amyloid fibrils in vitro
(Gustavsson et al., 1991) exhibiting a typical cross- con-
formation in x-ray diffraction studies (Jarvis et al., 1993).
The second type of fibril is assembled from the 90-residue,
predominantly -sheet, SH3 domain of bovine phosphati-
dylinositol-3-kinase (PI-3-kinase; Guijarro et al., 1998b).
A high-resolution structural model of these fibrils has been
constructed from cryoelectron microscopy data (Jime´nez et
al., 1999). The third type is assembled from the 130-residue
wild-type sequence of the human protein lysozyme. The
native structure of lysozyme contains both -helical and
-sheet domains, including four disulfide bonds. Lysozyme
has recently become the focus of intensive research due to
the isolation and characterization of two naturally occurring
mutants that give rise to a hereditary amyloidosis in humans
(Pepys et al., 1993; Booth et al., 1997; Canet et al., 1999),
and the recent finding that the well-characterized wild-type
protein also assembles to form fibrils (Morozova-Roche et
al., 2000).
MATERIALS AND METHODS
Fibril preparation
TTR10–19
TTR10–19 (CPLMVKVLDA) was synthesized on an Applied Biosystems
430A automated peptide synthesizer using standard Fmoc chemistry. After
cleavage from the support, the peptide was purified by reverse-phase
high-performance liquid chromatography (RP-HPLC) on a Beckman Sys-
tem Gold HPLC using either an analytical Brownlee 4.6  30 mm C8
reverse-phase column or a preparative Vydac 10  250 mm C-18 reverse
phase column. Fractions eluting from the column were analyzed by mass
spectrometry, and those of the desired molecular weight were pooled and
lyophilized.
Amyloid fibrils were formed by dissolution of TTR10–19 at 10 mg/ml in
10% (v/v) CH3COOH, pH 2, followed by incubation for 7–14 days at room
temperature. Fibril formation was assessed by transmission electron mi-
croscopy and by the observation of -sheet secondary structure by circular
dichroism spectroscopy. The reducing agent dithiothreitol (DTT) was
added to fibril preparations to determine whether elimination of disulfide
bonds influenced the morphology of fibrils formed in acidic solution. The
results indicate that reduction of the cysteine residue at position 1 in the
peptide sequence does not detectably influence the fibril ultrastructure as
assessed by electron microscopy (EM). Typically, the percentage of pep-
tide present as disulfide-linked dimers in peptide preparations was 20%,
as determined by MALDI-TOF mass spectrometry.
SH3 domain
The recombinant SH3 domain used in this study consists of 84 residues
derived from the p85 subunit of bovine PI-3-kinase plus a two-residue
(Gly-Ser) N-terminal extension and a four-residue (Trp-Asn-Ser-Ser) C-
terminal extension. The expression and purification procedures used here
have been described previously (Booker et al., 1993; Guijarro et al.,
1998a). Briefly, the polypeptide was expressed in Escherichia coli strain
BL21 as a fusion to glutathione S transferase. After induction with isopro-
pyl--D-thiogalactopyranoside, the fusion protein was purified over a GST-
Sepharose column, cleaved with thrombin, and further purified through
Mono Q ion exchange and S-100 size exclusion columns. The purified
protein was dialyzed into 20 mM ammonium bicarbonate and lyophilized.
Fibrils were generated by dissolving the protein to 0.5 mM in D2O adjusted
to pH 2.0 (isotope corrected) with DCl and allowing prolonged (2 weeks)
incubation at 35°C. Fourier transform infrared spectroscopy and EM were
employed to assess fibril formation.
Metal shadowing of SH3 amyloid fibrils
Samples containing SH3 domain amyloid fibrils (prepared as indicated
above) were diluted 50-fold and sprayed onto a freshly cleaved mica sheet.
The sheets were vacuum dried before platinum shadowing was carried out
by melting a small portion of platinum wire onto a carbon rod and
evaporating the metal onto the sample using a conventional carbon coater
(positioning the mica sheets at an angle of 15° to the surface). The plates
were then placed flat and coated with carbon. Samples were left at 37°C for
24 h and then floated onto water, and the film obtained was laid onto
acetone-cleaned nickel grids. The grids were placed on filter paper and left
to dry for 12 h at room temperature before analysis by EM.
Lysozyme
Human wild-type lysozyme, expressed and purified from Aspergillus niger
as described previously (Spencer et al., 1999), was prepared by Andrew
Spencer (Institute of Food Research, Norwich, UK). Fibrils were generated
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by dissolving the protein to 10 mg/ml in 10 mM glycine buffer, pH 2, and
incubating for 2 weeks or more at 57°C (Morozova-Roche et al., 2000).
Fibril formation was assessed by EM.
Atomic force microscopy
Ambient imaging
For ambient imaging, fibril samples (0.5–50 g/ml) were deposited on
freshly cleaved mica (Agar Scientific, Cambridge, UK) and dried overnight
at room temperature. Experiments were carried out with a MultiMode
microscope (Digital Instruments, Ltd., U.K.) in conjunction with a Nano-
scope IIIa control system. Both “E” and “J” scanners were used, with
lateral ranges of 10 m and 125 m, respectively. Etched silicon
probes, attached to triangular cantilevers 100–200 m in length (Digital
Instruments, model TESP), were operated at resonances in the 300–400
kHz range (drive 400-1500 mV). Height, amplitude, and phase data were
simultaneously collected, the latter with a Digital Instruments phase ex-
tender module. Before imaging, scanner calibration in the xy plane was
checked through the use of a 1-m calibration grid (LOT Oriel, Surry,
U.K.) and in the z direction by imaging atomic steps on a cleaved highly
orientated pyrolytic graphite surface. Solutions of suspended fibrils were
gently agitated to ensure that selected aliquots were representative of the
sample bulk. Samples were engaged at zero scan size to minimize possible
contamination (biofouling) of the probe. Topographic data were regularly
recorded simultaneously in trace and retrace to check for scan artifacts.
Scan rates were 1–5 Hz.
Fluid phase imaging
Fluid phase imaging was carried out by depositing fibril solutions (0.5–50
g/ml) on freshly cleaved mica and allowing the samples to stand for
10–30 min. The mica surface was then washed under a gentle stream of the
buffer solution appropriate for imaging (see below) and placed into the
Digital Instruments fluid cell. The cell was used without the supplied
O-ring. Imaging was generally carried out under deionized water (18.2
M, USF Elga, Buckinghamshire, U.K.), although to exclude the possi-
bility of nonspecific electrostatic effects between the sample and the tip,
lysozyme fibrils were also imaged under 15 and 100 mM potassium
phosphate buffer, pH 7.4. Silicon nitride cantilevers (NP-STT), force
constant 0.48 N/m (Digital Instruments) were used at a resonant frequency
of 7–9 kHz. Data sets were subjected to a first-order flattening and low
band pass filtering only where stated. Thermal noise levels are estimated to
be  0.1 nm. Fibril heights are estimated to be accurate to 0.4 nm on the
basis of the cross-sectional baseline errors.
RESULTS
TTR10–19 fibrils
Recent studies of amyloid fibrils by AFM are almost
equally divided between those performed on fibril samples
dried on a surface (Roher et al., 1996; Ionescu-Zanetti et al.,
1999; Kayed et al., 1999; Blackley et al., 1999; Harper et
al., 1999) and those performed under solvent (Mu¨ller et al.,
1997; Goldsbury et al., 1999; Kowalewski and Holtzman,
1999; Lin et al., 1999). Fig. 1 compares fibrils assembled
from TTR10–19 and observed by standard EM techniques
(Fig. 1 A) with AFM images of fibrils deposited on freshly
cleaved mica and dried overnight at room temperature (Fig.
1 B) or deposited and imaged under water (Fig. 1 C). The
visible structural features are qualitatively similar in each
case, although the fibrils imaged by AFM are significantly
broadened due to convolution effects arising from the finite
width of the AFM tip. All fibril dimensions were therefore
estimated from the height of the fibril in cross section.
Interestingly, the diameters of the fibrils estimated from
electron micrographs or from AFM images acquired in air
are significantly (1–2 nm) larger than the fibril diameters
estimated from AFM images acquired under fluid. The
average diameter of TTR10–19 fibrils estimated from EM
data is 6.2 nm, although we estimate the error associated
with this measurement to be as high as 1.5 nm. This value
agrees well with the diameter of air-dried TTR10–19 fibrils
estimated from AFM data (5.6 nm  0.6 nm). In contrast,
FIGURE 1 Images of fibrils assembled from TTR10–19. (A) Transmission electron micrograph of uranyl acetate negatively stained fibrils. Scale bar, 200
nm. (B) Amplitude AFM image of TTR10–19 fibrils dried on the mica surface. Note that the fibril widths appear much larger in the AFM images than in
electron micrographs due to convolution of surface features with the scanning tip. Scale bar, 200 nm. (C) Amplitude AFM image of TTR10–19 fibrils imaged
in solution. The data have been subjected to a first-order flattening. Scale bar, 200 nm. Note that data within amplitude images represent an error signal.
Although accentuating certain surface features, such images contain no true height information.
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the average diameter of the fibrils imaged in solution by
AFM is 4.4 nm (Fig. 2 A). A similar phenomenon has been
noted by Goldsbury and coworkers (1999), who compared
the dimensions of amylin fibrils imaged by EM with those
grown in situ and monitored by AFM. Vertical measure-
ments of biomolecules by AFM are free from the convolu-
tion effects associated with lateral measurements. They are,
however, commonly inconsistent with crystallographic data,
as a result of mechanical and electrostatic contributions to
the imaging process. Goldsbury et al. ascribed their obser-
vations, in part, to electrostatic effects. In comparing data
obtained in 100 mM potassium phosphate buffer with that in
pure, deionized, water, we conclude that these effects are
negligible. Instead, we ascribe the apparent discrepancy
between the diameters of fibrils imaged in air and in solu-
tion primarily to the flexibility of hydrated biological spec-
imens in response to the force applied by the oscillating
AFM tip.
SH3 domain fibrils
EM and AFM images of SH3 domain fibrils are shown in
Fig. 3, A and B, respectively. Once again, comparison of the
AFM images with EM data indicates significant broadening
of the apparent fibril width due to convolution with the
AFM tip. The fundamental features of the fibrils are, none-
theless, similar. Unlike the TTR10–19 fibrils, which appear
fairly uniform with respect to the fibril diameter, the struc-
tures assembled from the SH3 domain are highly heteroge-
neous and are made up of tubular fibrils, flat ribbons and
twisted sheets. When the dimension of the fibrils are, once
again, estimated from the height of the fibril in cross sec-
tion, the heterogeneity in fibril structure gives rise to a very
broad distribution of fibril diameters (Fig. 2 B). A different
aspect of this variability is illustrated in Fig. 4 A, which
shows a single SH3 domain fibril with a clearly visible
left-handed twist that repeats along the fibril length. The
handedness of this twist repeat was confirmed by EM of a
fibril stained by unidirectional platinum shadowing as dem-
onstrated in Fig. 4 B. The periodicity of this repeat is 104 
16 nm, and when viewed in cross section (Fig. 4 C) the fibril
height oscillates between 11 nm and 6 nm. In such
twisted structures the measured fibril height will clearly
depend on the point at which it is measured along the fibril
length.
The mean heights of individual fibrils were found to
extend across a broad range of values. The fibril shown in
Fig. 4 A, for example, has a height of 7.8 0.6 nm, whereas
others within the same sample ranged between 2 and 9 nm.
Variations in the average fibril height have previously been
ascribed to discrete populations of fibrils containing vari-
able numbers of the protofilaments that make up the fibril
substructure (Ionescu-Zanetti et al., 1999). On the basis of
this assumption, and in the light of information derived from
cryo-EM data (Jime´nez et al., 1999), it is possible to tenta-
tively assign the 7.8-nm fibrils as those containing four
protofilaments, whereas fibrils with heights in the 4-nm
range (Fig. 4 C) probably contain two protofilaments. An
alternative explanation, however, is that the loosely twisted
ribbon-like fibrils and the tightly twisted tubular fibrils are
different forms of the same basic structure. Within this
FIGURE 2 The dimensions of amyloid fibrils analyzed by AFM. (A) The
diameter of TTR10–19 fibrils was assessed by measuring the height in cross
section of 200 individual fibrils. The diameter of SH3 domain (B) and
lysozyme (C) fibrils was assessed by measuring the height in cross section
of 150 individual fibrils. The broad distribution of diameters arises
principally from structural heterogeneity within the fibrils. The data in each
case have been fitted to a modified gaussian distribution for clarity (solid
lines).
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argument, then, the compactness of tubular fibrils is due to
a change in the periodicity of the fibril twist. As with any
elastic compound, a decrease in the twist repeat (a tighter
twist) will give rise to an increase in the average diameter of
the fibril. This hypothesis is supported by the observation
that a fibril with an average diameter of 4.3 nm (Fig. 4 C)
has an average repeat periodicity of 156  16 nm and is
thus less tightly twisted than the fibril with an average
diameter of 7.8 nm. A low-diameter fibril with a long twist
repeat is suggestive of a loosely coiled ribbon-like topog-
FIGURE 3 The structure of fibrils
assembled from the SH3 domain of
PI-3-kinase. (A) Transmission elec-
tron micrograph of uranyl acetate
negatively stained fibrils. Scale bar,
200 nm. (B) Height AFM image of
SH3 domain fibrils imaged in solu-
tion. Scale bar, 200 nm; z-scale,
0 –90 nm.
FIGURE 4 The fine structure of amyloid fibrils assembled from the SH3 domain of PI-3-kinase. (A) Height AFM image of an SH3 domain fibril in
solution. The twist repeat along the fibril axis is left-handed, with a periodicity of 104  16 nm. Scale bar, 200 nm. (B) The handedness of the twist repeat
is confirmed by electron microscopy of an SH3 domain fibril stained using unidirectional platinum shadowing. Scale bar, 200 nm. (C) Fibril height profiles
along the axis of two fibrils with differing periodicities. The thinner fibril (average diameter, 4.3 nm; dotted line) has a longer axial repeat distance (156 
16 nm) than the larger fibril (average diameter, 7.8 nm; solid line).
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raphy. A linear relationship between fibril diameter and
helical repeat periodicity was applicable to the majority of
SH3 domain fibrils examined.
A single ribbon-like SH3 domain fibril is shown in
greater detail in Fig. 5. The fibril consists of clearly resolved
substructures or protofilaments. A cross section taken
through the fibril gives rise to the height profile shown in
Fig. 5 B. We estimate the diameter of each protofilament to
be approximately 2.3 nm by dividing the dimensions mea-
sured in cross section by a normalization factor (calculated
with the simplifying assumption of a cylindrical cross
section).
Human wild-type lysozyme fibrils
A similar arrangement of protofilaments to that of the SH3
domain fibrils is observed in fibrils assembled from the
130-residue protein lysozyme. Fig. 6 A shows fluid-phase
imaging of a single lysozyme fibril that splays apart into
four individual protofilaments. The lateral association of
two protofilaments is shown in Fig. 6 B. The material
observed in the background of both images is assumed to be
small aggregates of the protein deposited on the mica sur-
face. Protofilament diameters were measured from cross-
sectional heights only in regions of the image where this
amorphous material was not present. The lysozyme proto-
filaments have a diameter of 4.8–5.0 nm, more than twice
the size of the SH3 domain protofilaments. These appear to
coil together to form the numerous types of fibrils observed
by EM and AFM; a typical selection is presented in Fig. 7.
The fibril imaged by AFM and indicated by a solid arrow in
Fig. 7 B, for example, consists of two substructures that coil
in a left-handed manner to generate a loosely packed fibril
with a regular axial crossover repeat interval of 200 nm.
Each substructure appears to consist of two coiled proto-
filaments, as each is too large (8.3 nm diameter) to be a
single protofilament. Thus, this loosely coiled fibril appears
to be made up of four protofilaments arranged within a
double helix. Also present in the AFM image presented in
Fig. 7 B are several tubular fibrils, with axial crossover
repeats exhibiting periodicities ranging from 80–160 nm.
The diverse range of lysozyme fibril structures observed by
AFM is therefore the reason for measured diameters, as with
fibrils measured from the SH3 domain, crossing a broad
distribution of values (Fig. 2 C).
DISCUSSION
AFM has been applied to the imaging of numerous fibrous
systems of biological interest, including collagen and kera-
tin (Gale et al., 1995; Paige et al., 1998; Parbhu et al., 1999),
the paired helical filaments (PHFs) that make up a second
pathological indicator of Alzheimer’s disease (Pollanen et
al., 1997), and amyloid fibrils (Roher et al., 1996; Conway
et al., 1998; Wong et al., 1998; Harper et al., 1997a,b;
1999). Such is the power of fluid-phase imaging that it has
enabled investigation of the superstructure of living cells
(Henderson et al., 1992; Kasas et al., 1993) and the real-
FIGURE 5 The fine structure of
ribbon-like fibrils assembled from
the SH3 domain. (A) Amplitude
AFM image of a single amyloid fibril
showing a loose twist of the ribbon-
like structure containing four proto-
filaments. The image data have been
low bandpass filtered to reduce noise
and subjected to a first-order flatten-
ing. (B) Cross section profile for the
fibril presented in A. (C) Transmis-
sion electron micrograph of a SH3
domain ribbon-like fibril. Scale bar,
100 nm.
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time growth of amyloid fibrils (Goldsbury et al., 1999). We
have applied this technique to an investigation of the ultra-
structural organization of three types of amyloid fibril that
we prepare in the laboratory and have no known role in any
human disease.
The ultrastructure of amyloid fibrils has been studied by
numerous methods, including EM, x-ray diffraction, AFM,
molecular modeling, and solid-state NMR. Data describing
amyloid fibrils formed from a variety of protein precursors
are summarized in Table 1. Most of the fibril systems that
have been studied in detail previously were first recognized
for their importance in human diseases, and, other than the
SH3 domain and acylphosphatase, all of the proteins listed
in Table 1 are related to disease processes. Some general
trends appear to be common to fibrils formed by all pro-
teins. The basic structural units, the protofilaments, are of
the order of 2–5 nm in diameter and appear to be composed
of between two and six -sheets, depending on the protein
system under investigation. The size of the protofilament is
dictated by the association of -sheets but is not related to
the number of amino acid residues of the protein precursor.
Thus, an 11-residue peptide derived from apo-SAA appears
to form the largest protofilaments, comprising a putative six
-sheets, whereas the 90-residue SH3 domain forms proto-
filaments approximately 2 nm in diameter and apparently
consisting of only two -sheets. We predict from the di-
mensions of the human wild-type lysozyme protofilament
measured by AFM (4.8–5.0 nm) that this 130-residue pro-
tein forms protofilaments comprising four -sheets, similar
to the protofilaments formed by transthyretin. The consis-
FIGURE 6 The fine structure of
human wild-type lysozyme fibrils.
(A) Three-dimensional AFM height
image of a single lysozyme fibril that
splays apart to form four distinct pro-
tofilaments. Each protofilament has
an average diameter of close to 6.2
nm. z-scale, 0–30 nm. (B) A high-
magnification amplitude AFM image
showing the association of two pro-
tofilaments (each of 6–6.5 nm diam-
eter). Scale bar, 200 nm; z-scale,
0–70 nm.
FIGURE 7 The structure of fibrils assembled from human lysozyme. (A) Transmission electron micrograph of uranyl acetate negatively stained fibrils.
Scale bar, 200 nm. (B) Amplitude AFM image of lysozyme fibrils in solution. Scale bar, 400 nm.
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tency of the data within Table 1 and the similarity of our
data to amyloid fibrils related to human disease support a
general mechanism for amyloid assembly.
No information at present can be obtained on the sub-
structure of fibrils assembled from TTR10–19, because the
AFM data indicate that they are remarkably uniform with
respect to diameter. There is no evidence of the periodicity
typical of both the SH3 domain and lysozyme fibrils.
TTR10–19 protofilaments have, however, been observed pre-
viously in the presence of low concentrations of denaturant
that appears to perturb inter-protofilament interactions
(MacPhee and Dobson, 2000). These results suggest that the
protofilament packing that drives the assembly of fibrils of
TTR10–19 is relatively uniform, given the narrow distribu-
tion of fibril dimensions, and gives rise to a highly stable
structure.
The fibril preparations described in the current work were
all incubated for at least 2 weeks before examination by
AFM and hence consist primarily of mature fibrils. We have
chosen to refer to the relatively straight and long (500-
nm) fibril substructures observed by AFM and EM as pro-
tofilaments. Harper et al., (1997a,b) use the term protofila-
ment to refer to the short and flexible structures present in
immature fibril samples, and to the relatively long and
straight substructures within mature fibrils as filaments or
filamentous subunits. In contrast, Goldsbury et al. (1997,
1999) refer to the smallest unit structures of mature fibrils as
protofilaments, described as having long, relatively rigid
substructures. This definition derives from early observa-
tions dating back to the pioneering work of Cohen and
others (see Cohen et al., 1982, for review) describing the
ultrastructure of amyloid fibrils by electron microscopy of
thin tissue sections. The distinction between these two def-
initions is, at least in part, a temporal one, as Harper and
coworkers use the term protofilament to describe a structure
that later assembles into mature fibrils.
It is useful to compare the conclusions of a cryo-EM
study of SH3 domain fibrils (Jime´nez et al., 1999) with the
AFM data presented here. The estimated size of the proto-
filaments observed within twisted ribbons by AFM (2.3 nm)
agrees remarkably well with the model of a twisted fibril
generated from cryo-EM data (2 nm), and the observation
of four protofilaments by AFM is, again, consistent with
this. Both EM and AFM also show the formation of fibrils
with differing morphology, the diversity apparently arising
from the organization of the protofilaments within the fibril.
The cryo-EM fibril model consists of four protofilaments
super-coiled as a double helix along the length of the fiber
axis. In other fibrils, observed both by AFM and in cryo-EM
samples, the four protofilaments appear to be twisted as a
single unit around the axis of the fiber, giving rise to a
ribbon-like structure rather than a tubular fibril. It is unclear
whether the ribbon-like structures are closely related to the
tubular fibrils or whether these two types of fibril represent
distinct arrangements of the protofilaments. Analysis of our
AFM data suggests, however, that at least a proportion of
fibrils differ only in the tightness of the helical pitch of the
four laterally associated protofilaments along the long axis
of the fibril (Fig. 4 C). It is possible, therefore, that the
tubular fibrils merely represent the tightest possible twist of
the protofilament ribbon about the fibril axis.
The protofilaments within the assembled fibril of the SH3
domain could be four independent units or two pairs of
protofilaments where the -sheets within each are joined by
a stretch of unstructured polypeptide chain. Cryo-EM dif-
fraction data indicate an apparent twofold axis of symmetry
in the electron density, which is perhaps suggestive of a
covalent linkage between the two protofilaments (Jime´nez
et al., 1999). Neither structural arrangement can, however,
be unequivocally confirmed by the AFM data. Although
four substructures can be observed (Fig. 5) in many of the
SH3 domain fibrils examined by AFM, splitting of the
TABLE 1 Amyloid fibril data
Fibril subunit
Number of
residues
Diameter of
protofilament (Å)
Number of sheets/
protofilament
Diameter of
fibril (Å)
Number of
protofilaments/fibril Reference
A(14–23) 10 40 2 N/A N/A Tjernberg et al., 1999
A(6–25) 20 25–30 2 50–80 5–6 Fraser et al., 1991
A(12–42) 31 40 4 N/A N/A Li et al., 1999
A(1–40) 40 30–40 N/A 90 2 Harper et al., 1997a, b
A(1–40) 40 30 2 60–70 3–5 Malinchik et al., 1998
A(1–42) 42 25–30 2 60–120 3–6 Chaney et al., 1998
ApoSAA 11 50–60 4–6 N/A N/A Kirschner et al., 1998
Calcitonin 32 40 N/A 80 3 Bauer et al., 1995
Amylin (IAPP) 37 24–50 N/A 80–130 2–4 Goldsbury et al., 1997; 1999
PrPSc (90–145) 56 40 2 80–100 4 Inouye and Kirschner, 1997
SH3 domain 90 20 2 100–130 4 Jime´nez et al., 1999
Acylphosphatase 98 30–50 N/A 800–1500 100 Chiti et al., 1999
Ig light chain 108? 24 N/A 60–91 4–6 Ionescu-Zanetti et al., 1999
Transthyretin 127 40–50 4 130 4 Serpell et al., 1995
Transthyretin 127 20 2 80–120 4 Inouye et al., 1998
PrPres 200 30–50 N/A 70–90 2 Merz et al., 1983
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fibrils into independent substructures, as seen for human
wild-type lysozyme, was not detected in the analyzed sam-
ples. A substructure composed of two covalently linked
protofilaments could still give rise to both the twisted rib-
bons and compact tubular fibrils observed in SH3 domain
fibril preparations.
Formation of mature fibrils by protofilament self-associ-
ation appears to be influenced by the nature of the constit-
uent protein species. Fibrils assembled from an immuno-
globulin light chain have been classified into two classes:
type I and type II fibrils consisting of six or four protofila-
ments, respectively (Ionescu-Zanetti et al., 1999). Islet amy-
loid polypeptide (amylin), the amyloidogenic protein pre-
cursor implicated in type-II diabetes, displays further
polymorphism, forming discrete ribbons consisting of two,
three, or four laterally associated protofilaments, tubular
fibrils, and occasionally flat sheets (Goldsbury et al., 1997).
Importantly, fibril morphology is also sensitive to the con-
ditions under which the fibrils are formed. Human calcito-
nin fibrils assembled in vitro display significant morpho-
logical polymorphism that correlates with the history and
concentration of solutions of the protein precursor (Bauer et
al., 1995). A large body of evidence is available suggesting
that the morphology and biological behavior (Busciglio et
al., 1992; Seilheimer et al., 1997) of the A peptide impli-
cated in Alzheimer’s disease is related both to solvent
exposure before amyloid assembly and to the exact condi-
tions employed for fibril growth (Shen et al., 1994; Soto and
Frangione, 1995; Shen and Murphy, 1995).
The question therefore arises as to how the specific
protein sequence and the local environment affect the asso-
ciation of the protofilaments and give rise to a heteroge-
neous population of fibrillar structures. The ready formation
of amyloid by a 10-residue peptide derived from the se-
quence of the Alzheimer’s-related protein A (Tjernberg et
al., 1999) or a nine-residue peptide derived from the se-
quence of gelsolin (Maury et al., 1994) suggests that the
cooperative association of only short regions of a protein is
sufficient to generate a remarkably stable fibril structure.
The importance of the protein main chain in the structure of
amyloid, especially the -sheet core of the protofilaments,
provides an explanation for the formation of amyloid fibrils
with a common structure by a wide variety of structurally
unrelated proteins. It is likely, therefore, that the morpho-
logical diversity of the fibrils subsequently formed from the
protofilaments arises from heterogeneous packing of those
regions of the polypeptide chain that do not contribute to the
-sheet backbone but make up the interface between the
protofilaments. These regions of polypeptide chain are
likely to be disordered relative to the -sheet structure of the
amyloid fibrils. The presence of disordered material is ev-
ident from the electron-sparse regions of cryo-EM data
acquired for SH3 domain fibrils and is thought to be com-
posed of regions of the polypeptide chain that join adjacent
-strands within the protofilaments (Jime´nez et al., 1999).
Amorphous regions of polypeptide have also been inferred
from x-ray diffraction studies of ex vivo and in vitro as-
sembled fibrils (Sunde et al., 1997; Inouye et al., 1998). It
should be noted, however, that so far there is no clear
evidence by other techniques (Fourier transform infrared or
circular dichroism) for the formation of a significant frac-
tion of the polypeptide chain in a random coil structure
within any type of amyloid fibril, suggesting that some
degree of secondary and tertiary structure exists in these
regions or that only a small proportion of the polypeptide
chain contributes to the inter-strand linkages.
Heterogeneity in the organization of the disordered re-
gions of the polypeptide chains would also provide a ready
explanation for the formation, by the SH3 domain, of amy-
loid ribbons that appear to be twisted to various degrees. If
such structures observed by AFM consist of four laterally
associated protofilaments making up a ribbon-like structure
that then twists to form progressively tighter tubular fibrils,
then the inter-protofilament interactions must be relatively
non specific to allow the protofilaments to reorganize rela-
tive to one another. The existence of disordered, amorphous
regions of the polypeptide chain would permit some degree
of flexibility in these interacting regions as the polypeptide
chain could be rearranged to form the optimal packing of
side chains at the interface and at the fibril surface. This
model of fibril assembly also accounts for the ability of
fibrils to mature and structurally rearrange with time (Seil-
heimer et al., 1997).
In all of the fibrils formed by the SH3 domain or human
lysozyme observed within this AFM study that display a
resolved twist repeat along the length of the fiber axis, the
handedness of the twist is always to the left. Indeed, in the
majority of cases where twisted fibril ultrastructures have
been reported, a left-handed coiling about the fiber axis has
been observed (Bauer et al., 1995; Goldsbury et al., 1997;
Harper et al., 1997a; Ionescu-Zanetti et al., 1999). A notable
exception to this are fibrils formed from peptides containing
all D-amino acids (Harper et al., 1997a). These exhibit a
right-handed coiling of the protofilaments, indicating that
the twisting of protofilaments along the fibril axis is dictated
by the chirality of the amino acids in the constituent protein
species.
An important question is whether amyloid fibrils purified
from tissue samples or prepared in vitro from disease-
associated polypeptides actually represent the structures
formed in vivo and implicated in the disease state itself.
High-resolution ultrastructural investigations of thin-layer
tissue sections by EM (Inoue and Kisilevsky, 1996; Inoue et
al., 1997, 1998a,b) suggest that in vivo amyloid deposits
consist of a core of amyloid P (AP) component and proteo-
glycans, surrounded by a loose network of heparan sulfate
proteoglycans and thin filaments (1 nm) of amyloidotic
protein. Inoue et al. (1998a,b) suggest that only on extrac-
tion of the amyloid material do the thin protein filaments
associate to form the structure typically thought of as amy-
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loid. It is therefore important to examine a wide range of
fibrillar structures in vitro and to investigate the binding of
secondary components such as AP and proteoglycans to the
fibrils. Integral to increasing our understanding of the struc-
ture and heterogeneity of amyloid samples, and the possible
relevance of this to the clinical heterogeneity of associated
disease states, will be the development of methods by which
the properties of individual fibrillar structures can be
probed. The ability to examine fibrils under solution by
AFM provides an opportunity to study interactions of these
with other molecules and to follow both the kinetics and
mechanisms of fibril growth and dissolution at a nanometer
resolution. Such investigations will provide a powerful
means of scrutinizing the process of fibrillogenesis with
renewed clarity as well as providing important information
about the specific behavior of polypeptides implicated in the
disease process in vivo.
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